Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Common Equity (2016 - 2025)

Coherus Oncology's Common Equity history spans 13 years, with the latest figure at $61.0 million for Q4 2025.

  • For Q4 2025, Common Equity rose 146.23% year-over-year to $61.0 million; the TTM value through Dec 2025 reached $61.0 million, up 146.23%, while the annual FY2025 figure was $61.0 million, 146.23% up from the prior year.
  • Common Equity for Q4 2025 was $61.0 million at Coherus Oncology, down from $87.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $156.2 million in Q2 2021 and bottomed at -$196.5 million in Q1 2023.
  • The 5-year median for Common Equity is -$83.0 million (2024), against an average of -$36.6 million.
  • The largest annual shift saw Common Equity tumbled 1664.17% in 2023 before it soared 242.47% in 2025.
  • A 5-year view of Common Equity shows it stood at $97.7 million in 2021, then crashed by 240.62% to -$137.4 million in 2022, then crashed by 40.76% to -$193.4 million in 2023, then skyrocketed by 31.76% to -$132.0 million in 2024, then soared by 146.23% to $61.0 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Common Equity are $61.0 million (Q4 2025), $87.8 million (Q3 2025), and $119.8 million (Q2 2025).